Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Non Operating Income (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Non Operating Income for 12 consecutive years, with $165000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non Operating Income rose 466.67% year-over-year to $165000.0, compared with a TTM value of $2.4 million through Sep 2025, up 140.08%, and an annual FY2024 reading of $1.6 million, down 35.93% over the prior year.
  • Non Operating Income was $165000.0 for Q3 2025 at Lisata Therapeutics, down from $476000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $1.9 million in Q4 2024 and bottomed at -$105000.0 in Q1 2025.
  • Average Non Operating Income over 3 years is $458600.0, with a median of $439000.0 recorded in 2024.
  • Peak annual rise in Non Operating Income hit 3500.0% in 2025, while the deepest fall reached 126.12% in 2025.
  • Year by year, Non Operating Income stood at $660000.0 in 2023, then skyrocketed by 183.64% to $1.9 million in 2024, then tumbled by 91.19% to $165000.0 in 2025.
  • Business Quant data shows Non Operating Income for LSTA at $165000.0 in Q3 2025, $476000.0 in Q2 2025, and -$105000.0 in Q1 2025.